Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$253.62 ▲ +3.97
(+1.59%)
MKT CAP: $36.90B • VOL: 1.30M
52W L $149 52W H $259
BIIB // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $9.89B | $9.68B | $9.84B |
| YoY Revenue Growth % | +2.2% | -1.6% | — |
| Gross Profit | $7.49B | $7.37B | — |
| Gross Margin % | 75.7% | 76.1% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $1.53B | $1.93B | $1.37B |
| Operating Margin % | 15.4% | 19.9% | 13.9% |
| Net Income (GAAP) | $1.29B | $1.63B | $1.16B |
| EBITDA (Normalized) | $1.65B | $2.05B | $1.72B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $2.20B | $2.88B | $1.55B |
| Capital Expenditures (CapEx) | $153.8M | $153.7M | $442.6M |
| Free Cash Flow (FCF) | $2.05B | $2.72B | $1.10B |
| FCF Margin % | 20.7% | 28.1% | 11.2% |
| Return on Invested Capital (ROIC %) | 6.0% | 8.1% | 8.8% |
| Cash & Short-Term Equivalents | — | — | — |
| Total Debt (Short + Long Term) | $5.03B | $5.10B | $4.75B |
| Total Stockholders' Equity | $18.26B | $16.72B | $9.74B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BIIB.